Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences

DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®)   Encouraging signs of efficacy observed…

Read More

Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden

Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is pleased to announce the appointment of Axlab A/S as its exclusive distribution partner…

Read More

Penthrox is recommended for use in all UK ambulances

Medical Developments International Ltd (ASX: MVP) is delighted to advise the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) has issued its new pain management clinical practice guidelines for UK ambulance services teams. The JRCALC guidelines now recommend the…

Read More

Victoria’s new Boston office to help connect our world class med tech & pharma sector to key North American markets

The Andrews Labor Government today further expanded its international trade network with the opening of a new trade office in Boston. Minister for Small Business, Innovation and Trade Philp Dalidakis formally opened the new Victorian Government Trade and…

Read More

U.S. Patent Granted for Cynata Cymerus™ Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.…

Read More

St Vincent’s Hospital Commences Global First APAS® In Situ Automated Evaluation

 Australian developed advanced pathology instrument reading and interpreting plates for faster diagnosis of infectious diseases  Centre of excellence laboratory to test automation efficiency in a busy real-life setting Adelaide, Australia, 27 September 2017: Australian medical technology…

Read More

5th October – BioWorkshop – Global Pathways to Pre-Clinical Development Success

Learn approaches on how to design your pre-clinical studies from the experts! This workshop will cover global technical and regulatory strategies for pre-clinical development of medicines, from small molecules and biologics, to cell and gene therapies. Attendees will…

Read More

September 2017 – Pharmaceutical Manufacturing: Driving Competitive Advantage for Victoria

Continued Discussions : Pharmaceutical Manufacturing: Driving Competitive Advantage for Victoria BioMelbourne Network convened a roundtable with Minister Wade Noonan, Minister Philip Dalidakis and 14 pharmaceutical and biotechnology companies who currently manufacture or develop products for manufacture in Victoria…

Read More

Speaking Opportunities: Devices + Diagnostics Lab March 2018 – Disruptive Diagnostics

We’re starting to work on the Program for the 2018 Devices + Diagnostics Lab which will take place on Tuesday 27th March next year. If you have any suggestions for speakers, topics or technologies that you would like…

Read More

Ask Industry Anything (Again) – Tuesday 28th November 2017

BioMelbourne Network – Bringing industry and academia together! In November 2016, we launched “Ask Industry Anything” a new event which gave tables of students and researchers from leading academic organisations the opportunity to ask leaders from the biotechnology,…

Read More

Hydrix & Panorama

Today it was announced that Panorama Synergy Limited (ASX: PSY) has entered into an agreement to fully acquire Hydrix through an asset purchase agreement. This is an exciting development for both companies with the Merged Group at the…

Read More

BTF – Medical technology investment to improve lives

The Turnbull Government will fund three medical breakthroughs to help people with severe disabilities walk again and support thousands of Australians facing crippling chronic back pain.A total of $13.3 million will be invested into high potential Australian innovations…

Read More


News & opinion

Member Directory